Investigational drug · Phase 2
BMS-986012
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Extensive-stage Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "BMS-986012"
First trial start
2021
Mar 17, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Extensive-stage Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986012" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06646276 · 530 participants (planned) · Start Feb 25, 2025 · Primary completion Aug 17, 2027
Drug: BMS-986489 (Atigotatug+Nivolumab); Atezolizumab and 2 more · For: Extensive-Stage Small Cell Lung Cancer
Sites: Daphne, Alabama; Hot Springs, Arkansas; Fort Myers, Florida · 183 sites in all
- A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04702880 · 135 participants · Start Mar 17, 2021 · Primary completion May 22, 2025
Drug: BMS-986012; Carboplatin and 2 more · For: Extensive-stage Small Cell Lung Cancer
Sites: Birmingham, Alabama; Hackensack, New Jersey; Durham, North Carolina · 39 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02247349 · 106 participants · Start Nov 14, 2014 · Primary completion Dec 21, 2022
Drug: BMS-986012 (anti-fucosyl-GM1); Nivolumab · For: Small Cell Lung Cancer
Sites: New York, New York; Durham, North Carolina; Winston-Salem, North Carolina · 16 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02815592 · 12 participants · Start Nov 28, 2016 · Primary completion Dec 15, 2019
Drug: BMS-986012; Cisplatin and 3 more · For: Small Cell Lung Cancer
Sites: Barcelona, Spain; Madrid, Spain; Majadahonda - Madrid, Spain · 4 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06799286 · 10 participants · Start May 7, 2025 · Primary completion Sep 9, 2026
Drug: BMS-986489 · For: Small Cell Lung Carcinoma
Sites: Beijing, China; Jinan, China; Linyi, China · 5 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02949895 · 7 participants · Start Nov 29, 2016 · Primary completion Aug 29, 2017
Drug: BMS-986012; Cisplatin and 1 more · For: Small Cell Lung Cancer
Sites: Takatsuki-shi, Japan; Chuo-ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles.
Jiang Z, Zhao F, Li B, et al. · BMC Cancer 2025
- BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.
Chu Q, Leighl NB, Surmont V, et al. · JTO Clin Res Rep 2022
- A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer.
Ponath P, Menezes D, Pan C, et al. · Clin Cancer Res 2018
- Feasibility assessment of a novel selective peptide derivatization strategy for sensitivity enhancement for the liquid chromatography/tandem mass spectrometry bioanalysis of protein therapeutics in serum.
Yuan L, Mai A, Aubry AF, et al. · Rapid Commun Mass Spectrom 2014
- Systematic investigation of orthogonal SPE sample preparation for the LC-MS/MS bioanalysis of a monoclonal antibody after pellet digestion.
Yuan L, Aubry AF, Arnold ME, et al. · Bioanalysis 2013
Also in development for Extensive-stage Small Cell Lung Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- Atigotatug+NivolumabBMS-986489Phase 31 trial
Bristol Myers Squibb · Extensive-Stage Small Cell Lung Cancer
- ECI830Phase 21 trial
Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.